Back
Pancreatic Neuroendocrine Tumors Are Characterized by Loss of Noxa Expression that Can be Recovered by the Proteasome Inhibitor Bortezomib
E. P. Slater, J. Waldmann, C. López, E. Matthäi, V. Fendrich, D. K. Bartsch
J. Cancer Ther. Vol.4 No.10, November 14, 2013  DOI: 10.4236/jct.2013.410A004
       (PDF  339K)     HTML     
Pancreatic Neuroendocrine Tumors in the 21st Century—An Update
Rani Kanthan, Jenna-Lynn Senger, Shahid Ahmed, Selliah Chandra Kanthan
J. Cancer Ther. Vol.8 No.13, December 15, 2017  DOI: 10.4236/jct.2017.813103
       (PDF  770K)     HTML      XML
A Case of Ectopic Growth Hormone Releasing Hormone (GHRH) from Pancreatic Neuroendocrine Tumor Resistant to Therapy
Ohoud Almohareb, Juan Rivera
Open J. Endocr. Metab. Dis. Vol.3 No.7, November 18, 2013  DOI: 10.4236/ojemd.2013.37037
       (PDF  144K)     HTML      XML
Disseminated Intravascular Coagulation in a Patient with Metastatic Pancreatic Neuroendocrine Tumour: A Case Report and Review of the Literature
Rhian Sian Davies, Toby Wells, Sarah Gwynne
Case Rep. Clin. Med. Vol.3 No.10, October 09, 2014  DOI: 10.4236/crcm.2014.310119
       (PDF  2797K)     HTML     
Primary Endometrial High Grade Neuroendocrine Carcinoma: A Case Report with Cytological, Histopathological and Immunohistochemical Features
Kazuhiro Kobayashi, Masashi Matsuyama, Fumimasa Etori, Naomi Kawaguchi, Kyoko Nambu, Asuka Sekiya, Yuka Hiraku, Kazushige Yamamoto, Naoki Watanabe, Tetsuya Yamada, Takuji Tanaka
Open J. Pathol. Vol.5 No.1, January 09, 2015  DOI: 10.4236/ojpathology.2015.51001
       (PDF  3717K)     HTML      XML
 
 
Top